Marshall Wace’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Marshall Wace’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-10,700	Closed	-$411K	–	2861
2023 Q2	$411K	Buy	+10,700	New	+$275K	﹤0.01%	2053
2022 Q3	–	Sell	-265,351	Closed	-$4.64M	–	3945
2022 Q2	$4.64M	Buy	265,351 +201,617	+316%	+$3.16M	0.01%	1396
2022 Q1	$1.04M	Sell	63,734 -123,293	-66%	-$1.68M	﹤0.01%	2432
2021 Q4	$3.05M	Buy	+187,027	New	+$2.66M	0.01%	1764
2019 Q4	–	Sell	-5,507	Closed	-$29K	–	2175
2019 Q3	$29K	Buy	+5,507	New	+$36.6K	﹤0.01%	1575
2016 Q2	–	Sell	-22,332	Closed	-$1.43M	–	1219
2016 Q1	$1.43M	Buy	+22,332	New	+$1.81M	0.01%	633

Marshall Wace's KDNY Position: Q3 2023 in Review

Marshall Wace sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 10,700 shares — an estimated $411K sold.

Marshall Wace first reported a position in KDNY in Q1 2016 and held it in 6 quarters. The position peaked at $4.64M in Q2 2022. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

Marshall Wace reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Marshall Wace sold 10,700 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $411K.
Marshall Wace first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2016 and held it in 6 quarters.
Marshall Wace's Chinook Therapeutics, Inc. Common Stock position peaked at $4.64M in Q2 2022.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Marshall Wace's 13F filing for Q3 2023, filed 14 Nov 2023.